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BCL6 is a transcriptional repressor that has important functions in lymphocyte differentiation and lymphomagenesis, but there have
been no reports of BCL6 expression in gastric cancers. In the present study, we investigated the BCL6 function in gastric cancers.
Treatment with TPA resulted in BCL6 degradation and cyclin D2 upregulation. This phenomenon was inhibited by the suppression of
the nuclear translocation of HB-EGF-CTF (C-terminal fragment of pro-HB-EGF). The HB-EGF-CTF nuclear translocation leads to the
interaction of BCL6 with HB-EGF-CTF and the nuclear export of BCL6, and after that BCL6 degradation was mediated by ubiquitin/
proteasome pathway. Real-time RT–PCR and siRNA targeting BCL6 revealed that BCL6 suppresses cyclin D2 expression. Our data
indicate that BCL6 interacts with nuclear-translocated HB-EGF-CTF and that the nuclear export and degradation of BCL6 induces
cyclin D2 upregulation. We performed immunohistochemical analyses of BCL6, HB-EGF and cyclin D2 in human gastric cancers. The
inverse correlation between BCL6 and cyclin D2 was also found in HB-EGF-positive human gastric cancers. BCL6 degradation caused
by the HB-EGF-CTF also might induce cyclin D2 expression in human gastric cancers. Inhibition of HB-EGF-CTF nuclear translocation
and maintenance of BCL6 function are important for the regulation of gastric cancer progression.
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BCL6 is a proto-oncogene located on chromosome 3q27 that
encodes a transcriptional repressor (Baron et al, 1993; Kerckaert
et al, 1993; Ye et al, 1993; Miki et al, 1994). BCL6 protein is a 92- to
98-kDa nuclear phosphoprotein that is produced at low levels in
multiple tissues and is expressed at high levels exclusively in
germinal centre B cells (Cattoretti et al, 1995; Onizuka et al, 1995).
The formation of germinal centres and the development of T-cell-
dependent humoral immune responses require BCL6 expression
(Dent et al, 1997; Ye et al, 1997). BCL6 has an important function
in germinal centre formation and the regulation of lymphocyte
function, differentiation, and survival. High levels of BCL6 gene
expression in non-Hodgkin’s lymphomas have a favourable
prognostic value (Alizadeh et al, 2000; Lossos et al, 2001). BCL6
contains an N-terminal BTB/POZ domain and six Kruppel-type
(C2H2) zinc-finger (ZnF) motifs in the C terminus (Dhordain et al,
1995). The BTB/POZ domain displays a conserved protein–protein
interaction motif and is required for the repressive activity of the
protein (Jardin et al, 2007). The BTB/POZ domain interacts
directly with the silencing mediator of retinoic acid and thyroid
hormone receptor corepressor (or its relative N-CoR) (Dhordain
et al, 1995, 1997). The ZnF motifs of BCL6 bind to DNA in
a sequence-specific manner, leading to the transcriptional
repression of target genes. The highest affinity site has a core
sequence of 9bp (TTCCT(A/C)GAA), and one of the target genes is
cyclin D2 (Dent et al, 2002; Jardin et al, 2007). Thus, BCL6 is
implicated in cell-cycle control by repressing cyclin D2. Recently,
Logarajah et al (2003) and Bos et al (2003) reported that BCL6 has
an important function in breast cancer. However, to our knowl-
edge, there have been no reports of BCL6 in gastric cancer.
Heparin-binding epidermal growth factor-like growth factor
(HB-EGF), a member of the EGF family, is synthesised as a
20- to 30-kDa type I transmembrane precursor (pro-HB-EGF)
(Higashiyama et al, 1991, 1992). Ectodomain shedding is the
process in which the pro-HB-EGF molecule is proteolytically
cleaved by a disintegrin and metalloprotease (ADAM) 9, 12, 10, or
17 to release a soluble form of HB-EGF (Izumi et al, 1998; Asakura
et al, 2002; Lemjabbar and Basbaum, 2002; Sunnarborg et al, 2002;
Yan et al, 2002). Ectodomain shedding yields an N-terminal
soluble ligand for the EGF receptor (HB-EGF) and a C-terminal
fragment (HB-EGF-CTF) consisting of the transmembrane and
cytoplasmic domains. The C-terminal fragment of HB-EGF is
translocated from the cytoplasm to the nucleus and binds to a
member of the BTB/POZ ZnF family, such as promyelocytic
leukaemia zinc finger (PLZF) or BCL6 (Nanba et al, 2003; Kinugasa
et al, 2007). This interaction reverses the transcriptional repression
of PLZF or BCL6.
Gastric cancer is the second most common cancer in the
world, accounting for B9% of all malignancies worldwide
(Hohenberger and Gretschel, 2003). Increased expression and
activation of EGFR and its ligands are causally associated with the
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sprogression of gastric cancer and poor prognosis (Barnard et al,
1995; D’Agnano et al, 1995). However, the exact mechanisms of
HB-EGF-CTF activation within the gastric cancer environment are
not fully understood.
In the present study, we investigated the interaction of BCL6
with HB-EGF-CTF and the mechanism of cyclin D2 expression by
this interaction in gastric cancer cell lines, which express
endogenous HB-EGF, BCL6, and cyclin D2. We also immuno-
histochemically studied 100 surgical specimens of advanced gastric
cancers to analyse the expression of HB-EGF, BCL6, and cyclin D2.
Our data indicate that BCL6 interacts with HB-EGF-CTF and that
this interaction might induce the cyclin D2 expression in human
gastric cancer.
MATERIALS AND METHODS
Materials
We purchased the following antibodies: rabbit anti-BCL6 mono-
clonal antibody (EP529Y; Epitomics, Burlingame, CA, USA); rabbit
anti-cyclin D2 polyclonal antibody (M-20: sc-593; Santa Cruz
Biotechnology, Santa Cruz, CA, USA); mouse anti-b-actin mono-
clonal antibody (Sigma-Aldrich, Tokyo, Japan); goat anti-HB-EGF
polyclonal antibody (PX04; R&D Systems, Minneapolis, MN, USA);
mouse anti-phospho-EGFR monoclonal antibody (9H2) and sheep
anti-EGFR polyclonal antibody (Upstate, Lake Placid, NY, USA);
and mouse anti-ubiquitin monoclonal antibody (P4D1), rabbit
phospho-p44/42 MAP (mitogen-activated protein) kinase
(Thr202/Tyr204) polyclonal antibody (D13.14.4E), rabbit p44/42
MAP kinase (MAPK) polyclonal antibody, and horseradish
peroxidase-conjugated anti-mouse IgG antibody (Cell Signaling
Technology, Beverly, MA, USA). The rabbit anti-HB-EGF-CTF
polyclonal antibody and metalloproteinase inhibitor, KB-R7785,
were kind gifts from Dr Higashiyama (Ehime University, Ehime,
Japan). We obtained 12-0-tetradecanoylphorbor-13-acetate (TPA)
and MEK 1/2 inhibitor U0126 from Cell Signaling Technology. The
EGFR tyrosine kinase inhibitor AG1478 was purchased from
Calbiochem (La Jolla, CA, USA).
Cell culture
Human gastric cancer cells from the MKN45 cell line (Japanese
Cancer Research Bank, No. 0254) were seeded in 6cm dishes at
a density of 2 10
6 cells per dish and cultured for 48h with RPMI-
1640 (Sigma Chemical Co., St Louis, MO, USA) supplemented with
10% fetal calf serum and 1% ampicillin and streptomycin in 5%
CO2. Human colon cancer cells HT29 were obtained from the
American Type Culture Collection (Rockville, MD, USA) and
human oesophageal cancer cells T.T were obtained from Health
Science Research Resources Bank (Osaka, Japan). Both HT29 and
T.T cells were cultured with Dulbecco’s modified Eagle’s medium
(Sigma Chemical Co.) supplemented with 10% fetal calf serum and
1% ampicillin and streptomycin in 5% CO2.
Western blotting
Subconfluent MKN45 cells were switched to serum-free medium
for 24h and then treated with TPA for the indicated times.
Metalloproteinase inhibitor KB-R7785, EGFR tyrosine kinase
inhibitor AG1478 and MEK 1/2 inhibitor U0126 were added to
the cell cultures for 60min before stimuli. Cells were washed with
PBS ( ) and subsequently dissolved in 1  cell lysis buffer
(Cell Signaling Technology) containing 20mmoll
 1 Tris-HCl (pH
7.5), 150mmoll
 1 NaCl, 1mmoll
 1 Na2EDTA, 1mmoll
 1 EGTA,
1% Triton, 2.5mmoll
 1 sodium pyrophosphate, 1mmoll
 1
b-glycerophosphate, 1mmoll
 1 Na3VO4, and 1mgml
 1 leupeptin.
After disruption using a Bioruptor sonicator (Cosmo Bio, Tokyo,
Japan) for 15s, lysates were centrifuged at 15000r.p.m. for 10min
at 41C. Each sample was normalised on an equal protein
concentration by using a protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). An equal quantity of 2  sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) sample
buffer (0.5moll
 1 Tris-HCl (pH 7.2), 1% SDS, 100mmoll
 1
b-mercaptoethanol, and 0.01% bromophenol blue) was added to
each sample, and then samples were boiled for 5min at 1001C.
Aliquots of boiled sample were fractioned on 7.5, 10, or 12.5%
SDS–PAGE and then transferred to nitrocellulose membranes
(Amersham Pharmacia Biotech, Buckinghamshire, England). The
membranes were blocked with 5% skimmed milk in PBS ( ) for
1h at room temperature. The membranes were incubated with an
appropriate antibody overnight at 41C and then washed with 0.05%
Tween 20 in PBS ( ) three times at 5min intervals. The
membranes were incubated with an appropriate secondary anti-
body for 1h at room temperature, followed by three washes with
0.05% Tween 20 in PBS ( ) at 5min intervals. Immunoreactive
proteins were visualised by using the ECL Plus western blotting
detection system (Amersham Biosciences, Buckinghamshire,
England). Filters were stripped and reprobed with monoclonal b-
actin antibody (Abcam Plc., Cambridge, MA, USA) as an internal
control.
siRNA
The siRNAs for the knockdown of BCL6 (siBCL6, CUGCGU
CAUGCUUGUGUUAUA) and a scrambled siRNA (GCGCGCUUU
GUAGGAUUCG), used as a negative control, were designed by and
obtained from Qiagen (Tokyo, Japan). The scrambled sequence did
not correspond to any mammalian sequence in the NCBI database
and was used as a control. MKN45 cells were transfected with
20mmoll
 1 siRNA by using Lipofectamine reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Assays were performed 2 days after MKN45 cells were transfected.
Real-time RT–PCR
Total RNA was isolated from cells by using TRIzol reagent
(Invitrogen). First-strand cDNA was synthesised by using Super-
script II (Invitrogen) according to the manufacturer’s instructions.
Primers for human cyclin D2 and control human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were obtained from Applied
Biosystems (Tokyo, Japan; cyclin D2, Hs0027041_m1; GAPDH,
4310884E). Real-time RT–PCR was carried out on the ABI 7500
Fast Real-Time PCR system (Applied Biosystems). Each experi-
ment was carried out in a 20ml reaction volume containing 18ml
TaqMan Fast Universal PCR Master Mix (Applied Biosystems), 1ml
cDNA, and 1ml primers. A uniform amplification of the products
was rechecked by analysing the melting curves of the amplified
products. All reactions were carried out in triplicate to assess
reproducibility.
Immunofluorescence microscopy
Human gastric cancer cells (MKN45) in a subconfluent state were
switched to serum-free medium for 24h and then treated with
200nmoll
 1 TPA at the indicated times, and the subcellular
localisation of HB-EGF-CTF and BCL6 was analysed by immuno-
fluorescence study. Cells were fixed with ethanol and acetone.
Incubation with primary antibodies was performed in a solution of
PBS containing 0.1% milk at room temperature. Then, sections
were incubated with the appropriate secondary antibodies and all
sections were counterstained with 40,6-diamidino-2-phenylindole
(DAPI; Kirkegaard and Perry Laboratories, Gaithersburg, MD,
USA). Images were obtained with an Eclipse 80i fluorescence
microscope (Nikon, Tokyo, Japan).
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Cells treated with TPA were lysed with 1ml of lysis buffer. After
centrifugation of the lysates at 15000r.p.m. for 20min, super-
natants were collected and incubated with 1mg of anti-HB-EGF-
CTF antibody or anti-BCL6 antibody for 2h at 41C with end-over-
end rotation. Next, 20ml of protein G Sepharose beads (50%
suspension; Amersham Pharmacia Biotech) was added to each
lysate/antibody mixture, followed by incubation for 2h at 41C with
end-over-end rotation. The mixtures were then centrifuged, and
the protein G Sepharose beads were washed three times with lysis
buffer, resuspended in 15mlo f2  SDS–PAGE sample buffer and
boiled for 3min. The bound proteins were analysed by western
blotting using an anti-BCL6 antibody or anti-ubiquitin antibody.
Samples and tissue collection
We performed immunohistochemical staining of tissue samples
from 100 cases of advanced gastric cancer that were surgically
resected at Nagoya City University Hospital between 1998 and
2004. All specimens were fixed in 10% buffered formalin. Gastric
cancers with adjacent non-neoplastic mucosa were cut serially into
4mm slices in parallel with the lesser curvature. The slices were
embedded in paraffin and stained with hematoxylin and eosin for
histological examination.
Immunohistochemistry
Immunohistochemical staining was performed with antibodies
against the following antigens: BCL6 (EP529Y, dilution 1:100;
Epitomics), cyclin D2 (M-20: sc-593, dilution 1:250; Santa Cruz
Biotechnology), and HB-EGF (PX04, dilution 1:50; R&D Systems).
The procedure was performed with the appropriate positive and
negative controls. The immunohistochemical techniques were
performed as previously described (Takenaka et al, 2007). Briefly,
4mm-thick consecutive sections were deparaffinised and hydrated
through a graded series of alcohols. After inhibition of endogenous
peroxidase activity by immersion in 3% H2O2/methanol solution,
antigen retrieval was achieved by heating the samples in 10mM
citrate buffer (pH 6.0) in a microwave oven for 10min at 981C.
Then, sections were incubated with primary antibodies. After
thorough washing in PBS ( ), the samples were incubated with
biotinylated secondary antibodies and then with avidin-biotin
horseradish peroxidase complexes (Vectastain Elite ABC kit;
Vector Laboratories Inc., Burlingame, CA, USA). Finally, immune
complexes were visualised by incubation with 0.01% H2O2 and
0.05% 3,30-diaminobenzidine tetrachloride. Nuclear counterstain-
ing was accomplished with Mayer’s hematoxylin.
Two independent researchers (YH and NO) judged the histology
and immunohistochemical staining of the HB-EGF, BCL6, and
cyclin D2. To investigate the relationship between HB-EGF, BCL6,
and cyclin D2 expression, we analysed immunohistochemical
staining of HB-EGF, BCL6, and cyclin D2 area by area. The
localisations of BCL6 were heterogeneous in the same cancer
tissues. However, we found 100 homogeneously stained regions
41cm in diameter. Only nuclear immunostainings were
considered to be positive for the evaluation of BCL6 and cyclin
D2 staining, whereas nuclear and cytoplasmic immunostainings
were considered to be positive for HB-EGF evaluation. Reactivity
for HB-EGF, BCL6, and cyclin D2 was scored according to the
percentage of positively stained tumour cells in the section areas
on a three-point scale: score 0 ( ),o10%; score 1 (þ), 10–33%;
score 2 (þþ), 34–66%; score 3 (þþþ), 67–100%. The
expression was considered to be positive (þ) with a score of 1
or higher (Mizoshita et al, 2003). When less than 10% of tumour
cells were stained, immunostaining was considered to be negative.
Statistical analysis
The data were analysed by Welch’s t-test and w
2-test, as
appropriate. P-values o0.05 were considered statistically signifi-
cant.
RESULTS
TPA-dependent ectodomain shedding induces
phosphorylation of both EGFR and MAPK in MKN45 cells
We first examined whether TPA treatment induces phosphoryla-
tion of both EGFR and MAPK in MKN45 cells. 12-0-Tetradeca-
noylphorbor-13-acetate was used to induce cleavage of pro-HB-
EGF by the activation of ADAM12. Cells were treated with 200nM
TPA for the indicated periods, after which the endogenous
phospho-EGFR and phospho-p44/42 MAPK, along with total
EGFR and total p44/42 MAPK expression levels, were analysed
by western blotting. Treatment with TPA resulted in phosphoryla-
tion of both EGFR and p44/42 MAPK in MKN45 cells (Figure 1A).
However, when 1mM AG1478, an EGFR tyrosine kinase inhibitor,
and 20mM U0126, an MEK 1/2 inhibitor, were added to inhibit the
EGFR signalling pathway before treatment with 200nM TPA,
phospho-EGFR
0 min
+
+
+
+
+
+
+
+
+
+ ++ + +
+
+
−
−
−
−
−
−
−
−
Total  EGFR
phospho-p44/42 MAPK
Total  p44/42 MAPK
15 min 240 min
TPA            
AG1478         
U0126
TPA            
AG1478         
U0126
phospho-EGFR
Total  EGFR
phospho-p44/42 MAPK
Total  p44/42 MAPK
200 nM
1 M
20 M
200 nM
1 M
20 M
120 min 0 min 15 min 240 min 120 min
Figure 1 12-0-Tetradecanoylphorbor-13-acetate (TPA)-dependent ectodomain shedding induces phosphorylation of both EGFR and MAPK in MKN45
cells. (A) MKN45 cells were treated with 200nM TPA for 0, 15, 120, and 240min respectively. The endogenous phospho-EGFR and phospho-p44/42
MAPK, along with total EGFR and total p44/42 MAPK expression levels, were analysed by western blotting. (B) Before the treatment of MKN45 cells with
200nM TPA for indicated periods, the cells were preincubated with 1mM AG1478 (an EGFR tyrosine kinase inhibitor) and 20mM U0126 (an MEK 1/2
inhibitor) for 60min. The endogenous phospho-EGFR and phospho-p44/42 MAPK, along with total EGFR and total p44/42 MAPK expression levels, were
analysed by western blotting.
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despite the TPA treatment in MKN45 cells (Figure 1B). Thus, these
data indicated that TPA-dependent ectodomain shedding induced
phosphorylation of both EGFR and MAPK, and AG1478 and U0126
inhibited the EGFR signalling pathway.
BCL6 expression is decreased and cyclin D2 expression is
increased following pro-HB-EGF shedding in MKN45 cells
We performed western blotting to investigate the expression of
endogenous pro-HB-EGF, BCL6, and cyclin D2 in MKN45 cells. We
found that MKN45 cells express endogenous pro-HB-EGF, BCL6,
and cyclin D2 (data not shown). We determined whether the
shedding of pro-HB-EGF could affect the expression of BCL6 and
cyclin D2 protein levels. Cells were treated with 200nM TPA for the
indicated periods, after which the endogenous BCL6 and cyclin D2
expression levels were analysed by western blotting. In the absence
of TPA, the level of cyclin D2 in MKN45 cells was low. However,
after the TPA treatment, cyclin D2 expression level increased
significantly, and BCL6 expression level was decreased (Figure 2A).
Thus, BCL6 expression is decreased and, inversely, cyclin
D2 expression is increased following pro-HB-EGF shedding in
MKN45 cells.
BCL6 degradation depends on HB-EGF-CTF nuclear
translocation
To confirm that the degradation of BCL6 and the upregulation of
cyclin D2 protein level depend on the production of HB-EGF-CTF,
we used AG1478 and U0126. Before treatment with 200nM TPA, for
the purpose of EGFR signalling pathway inhibition, the cultured
MKN45 cells were treated with 1mM AG1478 and 20mM U0126 for
60min. Despite the complete inhibition of the EGFR signalling
pathway (Figure 1B), BCL6 expression is decreased and cyclin D2
expression is increased after TPA treatment (Figure 2B). Then,
we used metalloproteinase inhibitor KB-R7785 as an inhibitor of
HB-EGF-CTF nuclear translocation by blocking the shedding of
HB-EGF through inhibition of ADAM12 (Shimura et al, 2008).
Before TPA stimuli, 10mM KB-R7785, with or without 1mMAG1478
and 20mM U0126, was added to the cells for 60min to suppress the
HB-EGF-CTF nuclear translocation. Despite the TPA treatment,
BCL6 and cyclin D2 expression levels were unchanged regardless
of the presence of inhibition of the EGFR signalling pathway
(Figure 2C and D). These results indicate that the degradation of
BCL6 and the upregulation of cyclin D2 depend on the production
and nuclear translocation of HB-EGF-CTF after pro-HB-EGF
shedding.
BCL6 suppresses cyclin D2 expression in MKN45 cells
To determine if the upregulation of cyclin D2 protein is associated
with BCL6, we transfected siRNA targeting BCL6 into MKN45 cells.
The protein level of BCL6 in MKN45 cells was specifically reduced
48h after transfection (Figure 3A). Cyclin D2 protein levels were
not affected by transfection of the scrambled siRNA (Figures 2A
and 3A). In BCL6 knockdown MKN45 cells, cyclin D2 protein level
was increased, even in the absence of TPA, compared with
untransfected cells (Figure 3A). We also evaluated cyclin D2
mRNA levels after TPA treatment to confirm that BCL6 regulates
transcription of cyclin D2. Real-time RT–PCR data revealed that
cyclin D2 mRNA levels were increased after TPA treatment
(Figure 3B). These results indicate that BCL6 suppresses cyclin D2
expression in MKN 45 cells.
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Figure 2 Nuclear translocation of HB-EGF-CTF induces degradation of BCL6 and upregulation of cyclin D2 expression. (A) MKN45 cells were treated
with 200nM TPA for 2 or 4h. The levels of BCL6 and cyclin D2 protein were determined by western blotting with anti-BCL6 and anti-cyclin D2 antibody.
(B) Before the treatment of MKN45 cells with 200nM TPA for 2 or 4h, the cells were preincubated with 1mM AG1478 and 20mM U0126 for 60min. The
levels of BCL6 and cyclin D2 protein were analysed by western blotting. (C) Before TPA stimuli, 10mM KB-R7785 (a metalloproteinase inhibitor) with both
1mM AG1478 and 20mM U0126 was added to the cells for 60min. Then, MKN45 cells were treated with 200nM TPA for 2 or 4h. The levels of BCL6 and
cyclin D2 protein were determined by western blotting. (D) Before TPA stimuli, 10mM KB-R7785 alone was added to the cells for 60min. Then, MKN45
cells were treated with 200nM TPA for 2 or 4h. The levels of BCL6 and cyclin D2 protein were determined by western blotting. The total incubation time
from the start of the TPA treatment to cell lysis is shown at the top of the panel. b-Actin was used as a loading control for western blotting.
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export of BCL6
To investigate the behaviour of endogenous HB-EGF-CTF and
BCL6 after TPA treatment, we performed immunostaining of HB-
EGF-CTF and BCL6 in MKN45 cells. Before the TPA treatment,
HB-EGF-CTF was predominantly localised in the cytoplasm,
whereas BCL6 was observed in the nucleus. Fluorescent images
revealed the translocation and accumulation of HB-EGF-CTF in
the nucleus after 1h of TPA treatment, whereas BCL6 remained in
the nucleus (Figure 4). This result is consistent with previous data
(Nanba et al, 2003). The nuclear export of BCL6 was detected after
2h of TPA treatment (Figure 4), and both HB-EGF-CTF and BCL6
were predominantly localised in the cytoplasm after 4h of TPA
treatment (Figure 4). Thus, the nuclear export of BCL6 occurred
after the nuclear translocation of HB-EGF-CTF was induced by
ectodomain shedding.
Interaction of BCL6 with HB-EGF-CTF increases after the
HB-EGF-CTF nuclear translocation
To analyse the amount of endogenous interaction between BCL6
and HB-EGF-CTF in MKN45 cells, we used antibodies against
the cytoplasmic region of pro-HB-EGF. After cells were treated
with 200nM TPA for the indicated periods, BCL6 was precipi-
tated from an extract of MKN45 cells by anti-HB-EGF-CTF
antibody and then detected by western blotting with an anti-
BCL6 antibody. Endogenous BCL6, which coimmunoprecipitated
with HB-EGF-CTF, reached its maximum level after 1h of TPA
treatment (Figure 5A). These results, together with fluorescent
images, indicate that nuclear BCL6 interacts with nuclear-translo-
cated HB-EGF-CTF and that this interaction causes the nuclear
export of BCL6.
Ubiquitin/proteasome pathway mediates BCL6
degradation
To determine the mechanism for BCL6 degradation, we attempted
to identify BCL6/ubiquitin conjugates. After treatment with 200nM
TPA for the indicated periods, cell lysates were collected and
subjected to immunoprecipitation with anti-BCL6 antibodies. The
immunoprecipitates were analysed by western blotting with anti-
ubiquitin antibody (Figure 5B). Typical ladders representing
multi-ubiquitinated forms of BCL6 were detected at high levels
after 4h of TPA treatment, suggesting that BCL6 degradation after
the nuclear export of BCL6 is mediated by the ubiquitin/
proteasome pathway.
BCL6 expression in human normal gastric epithelium and
other human tissues
We performed immunohistochemical staining of BCL6 in normal
gastric tissues from humans. BCL6 was expressed in normal gastric
epithelial cells, mainly in the bottom areas of gastric glandular
ducts (Figure 6A and B). In addition, we examined BCL6
expression of other human tissues (Figure 6C–F). BCL6 was not
expressed in normal mucosa of colon and oesophagus. We also
evaluated endogenous BCL6 expression in human colon and
oesophageal cancer cell lines by western blotting. These cancer cell
lines also did not express endogenous BCL6 protein (Figure 6G).
Immunohistochemical analysis of BCL6 in human gastric
cancers
The clinicopathological information from 100 cases of gastric
cancers is summarised in Table 1. The study group consisted of 67
men and 33 women, with a mean age of 65.4 years (range, 37–88
years). There were 45 differentiated gastric cancers and 55
undifferentiated gastric cancers. Of the 100 cases of gastric cancer,
24 were BCL6 positive (positive rate¼24%) and 76 cases were
BCL6 negative. In BCL6-positive cells, both the nucleus and the
cytoplasm were stained (Figure 7). There was a statistically
significant difference in the histological type of BCL6-positive vs
BCL6-negative cancers (Po0.05). BCL6 was highly expressed in
differentiated cancers and was remarkably reduced or absent in
undifferentiated cancers. There were no significant differences
in gender, depth of invasion, and lymph node metastasis between
the BCL6-positive and BCL6-negative groups (Table 1). In the
Kaplan–Meier analysis, survival curves showed no significant
differences between BCL6-positive and BCL6-negative cases
(data not shown).
Correlations between BCL6 and cyclin D2 expression
We analysed the relationship between BCL6 and cyclin D2
expression (Table 2). In the HB-EGF-positive group, statistically
significant differences in cyclin D2 expression were noted in the
BCL6-positive vs BCL6-negative subgroups (Po0.05) (Table 2A).
Thus, BCL6 expression appears to be closely correlated with the
downregulation of cyclin D2 expression. BCL6 was highly
expressed in cyclin D2-negative cases and was remarkably reduced
in cyclin D2-positive cancer cases in the HB-EGF-positive group.
These results indicate that degradation of BCL6 might also induce
cyclin D2 expression under the HB-EGF existence in human gastric
cancer tissues as well as a gastric cancer cell line. In the HB-EGF-
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Figure 3 BCL6 suppresses cyclin D2 expression. (A) The levels of endogenous BCL6 and cyclin D2 protein were assessed by western blotting with anti-
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snegative group, there were no significant differences in the
relationship between BCL6 and cyclin D2 expression (Table 2B).
DISCUSSION
In the present study, we found that the transcriptional repressor
BCL6 interacts with nuclear translocated HB-EGF-CTF after
ectodomain shedding and that this interaction caused the nuclear
export of BCL6. Cytoplasmic translocated BCL6 was degraded by
the ubiquitin/proteasome pathway, and the degradation of BCL6
induced cyclin D2 expression in gastric cancer cell lines that
expressed endogenous BCL6, HB-EGF-CTF, and cyclin D2. In the
HB-EGF-positive group of human gastric cancer samples, BCL6
expression is also inversely correlated with cyclin D2 expression.
We also identified a link between the expression of BCL6
(determined by immunohistochemistry) and the histological type
of human gastric cancers.
12-0-Tetradecanoylphorbor-13-acetate has previously been
demonstrated to induce cleavage of pro-HB-EGF by the activation
TPA 200 nM
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Figure 5 BCL6 interacts with HB-EGF-CTF and is degraded through the ubiquitin/proteasome pathway. (A) After treatment with 200nM TPA for the
indicated periods, HB-EGF-CTF was immunoprecipitated from an extract of MKN45 cells with anti-HB-EGF-CTF antibody and subsequently divided into
two equal aliquots. One aliquot was subjected to western blotting with an anti-BCL6 antibody, and the second aliquot was subjected to western blotting
with anti-HB-EGF-CTF antibody to control for loading. (B) After treatment with 200nM TPA for the indicated periods, BCL6 was immunoprecipitated from
an extract of MKN45 cells with anti-BCL6 antibody and subsequently divided into two equal aliquots. One aliquot was subjected to western blotting witha n
anti-ubiquitin antibody, and the second aliquot was subjected to western blotting with anti-BCL6 antibody to control for loading. M, size markers.
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Figure 4 Nuclear export of BCL6 is detected following nuclear translocation of HB-EGF-CTF after TPA treatment. HB-EGF-CTF (red) and BCL6 (green)
were visualised by immunofluorescent microscopy. Nuclei were stained blue by DAPI. MKN45 cells were treated with 200nM TPA for 4h. The total
incubation time is shown at the top of the panel.
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sof ADAM12 (Raab et al, 1994; Goishi et al, 1995; Asakura et al,
2002; Kurisaki et al, 2003; Higashiyama and Nanba, 2005). Our
result revealed that TPA-dependent ectodomain shedding induced
phosphorylation of both EGFR and MAPK. Treatment of MKN45
cells with TPA resulted in the degradation of BCL6 expression and
the upregulation of cyclin D2 protein. Despite the suppression of
EGFR signalling pathway, BCL6 protein level was decreased and
cyclin D2 expression level was increased after TPA treatment.
However, BCL6 degradation and cyclin D2 overexpression were
inhibited by the suppression of the nuclear translocation of HB-
EGF-CTF. Taking into account the interaction between BCL6 and
cyclin D2, it was reported that the ZnF motifs of BCL6 bind to the
cyclin D2 gene (Shaffer et al, 2000; Kinugasa et al, 2007).
Fernandez de Mattos et al (2004) reported that BCL6 repressed
cyclin D2 transcription through a STAT5/BCL6 site located within
the cyclin D2 promoter. In addition, our data reveal that the
knockdown of BCL6 increases the cyclin D2 protein level in
MKN45 cells, even in the absence of TPA, compared with
untransfected MKN45 cells and that cyclin D2 mRNA levels were
increased after TPA treatment. The mechanism that BCL6 regulate
transcription of cyclin D2 might also happen in gastric cancer cells.
Considering these facts, our data indicate that HB-EGF-CTF
nuclear translocation caused the degradation of BCL6 and that
this degradation reverses cyclin D2 repression in gastric cancer cell
lines that express endogenous BCL6, HB-EGF-CTF, and cyclin D2.
We used immunofluorescence microscopy to prove the nuclear
export of BCL6, and we used immunoprecipitation to show the
increased interaction of BCL6 with HB-EGF-CTF in MKN45 cells.
Nanba et al (2003) reported that subsequent to proteolytic cleavage
of pro-HB-EGF, HB-EGF-CTF was translocated from the cytoplasm
into the nucleus, and this translocation triggered the nuclear
export of PLZF. We proved a similar phenomenon in the case of
BCL6. The translocation of HB-EGF-CTF from the cytoplasm into
the nucleus and the nuclear export of BCL6 triggered by the
translocation of HB-EGF-CTF were confirmed after TPA treatment.
Immunoprecipitation revealed that the interaction of BCL6 with
HB-EGF-CTF increased after HB-EGF-CTF nuclear translocation.
These results indicate that nuclear BCL6 interacts with nuclear
translocated HB-EGF-CTF and that this interaction causes the
nuclear export of BCL6. Gene expression control by transcriptional
repression occurs in the nucleus, and the nuclear export of BCL6
MKN45
-Actin
A
CDG
BEF
BCL6
HT29 T.T
Figure 6 BCL6 expression in human normal gastric epithelium and other human tissues. (A and B) Immunohistochemical staining of human normal
gastric epithelium. (C and D) Immunohistochemical staining of human normal colon epithelium (E and F). Immunohistochemical staining of human normal
oesophageal epithelium. (Original magnification: A  100; C and E  200; B, D, and F  400). (G) The level of endogenous BCL6 protein of MKN45 cells,
along with HT29 cells (human colon cancer cell line) and T.T (human oesophageal cancer cell line), was analysed by western blotting for comparison.
Table 1 Clinicopathological factors and BCL6 expression in 100 gastric
cancers
BCL6 expression
Factor n Positive (score
a) Negative (score
a) P-value
Gender
Male 67 17 (2.71±0.14) 50 (0.00±0.00) 0.646
Female 33 7 (2.43±0.29) 26 (0.00±0.00)
Histological type
b
Differentiated 45 16 (2.82±0.10) 29 (0.00±0.00) 0.01
Undifferentiated 55 8 (2.25±0.31) 47 (0.00±0.00)
Depth of invasion
T1-2 40 12 (2.58±0.19) 28 (0.00±0.00) 0.3
T3-4 60 12 (2.67±0.18) 48 (0.00±0.00)
LN metastasis
Absence 25 6 (2.67±0.21) 19 (0.00±0.00) 1
Presence 75 18 (2.61±0.16) 57 (0.00±0.00)
Age (years)
(mean±s.d.) 65.6±10.7 65.2±12.0
n¼number of cases; LN¼lymph node.
aThe scores of each marker are average of
±standard error (s.e.).
bClassified based on structure of elements. ‘Differentiated’
includes tubular and papillary types, whereas ‘undifferentiated’ consists of signet-ring
and poorly differentiated types.
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sresulted in the loss of repressor function. Moreover, our data
revealed that multi-ubiquitinated forms of BCL6 were increased
after 4h of TPA treatment, suggesting that the BCL6 degradation
after the nuclear export of BCL6 is mediated by the ubiquitin/
proteasome pathway. Niu et al (1998) also reported that BCL6
degradation was mediated by the ubiquitin/proteasome pathway.
Considering these facts, our data clearly indicate that the nuclear
export of BCL6 triggered by both the nuclear translocation of
HB-EGF-CTF and the interaction of BCL6 with HB-EGF-CTF
results in the deregulation of BCL6 transcriptional repressor
function and the degradation of BCL6 through the ubiquitin/
proteasome pathway. Taking the results of western blotting data
into consideration, HB-EGF-CTF is translocated from the cyto-
plasm into the nucleus where it binds to BCL6. This interaction
causes nuclear export and degradation of BCL6 and might result in
the downregulation of BCL6 repressor activity for the cyclin D2
promoter in gastric cancer cells.
We also performed BCL6 immunohistochemistry on specimens
of human gastric cancers. To our knowledge, this is the first report
of an immunohistochemical analysis of BCL6 in human gastric
cancers. BCL6 was considered to be produced at low levels in
multiple tissues, and our immunohistochemical data revealed that
BCL6 was expressed in normal gastric epithelial cells, mainly in the
bottom areas of gastric glandular ducts. In the process of gastric
cancer progression, BCL6 is decreased by HB-EGF-CTF signalling
and the ubiquitin/proteasome pathway.
We found that BCL6 expression is closely linked with the
downregulation of cyclin D2, as determined by immuno-
histochemistry, in cases of HB-EGF-positive human gastric cancer.
Several studies have reported a correlation between decreased
expression of cyclin D2 in cell lines and increased expression of the
cell-cycle inhibitor p27
kip (Walz et al, 2006; Susaki et al, 2007).
Taking into account the interaction between BCL6 and cyclin D2, it
was reported that BCL6 repressed cyclin D2 transcription within
the cyclin D2 promoter in vitro (Shaffer et al, 2000; Fernandez de
Mattos et al, 2004; Kinugasa et al, 2007). In the present study, our
immunohistochemical analysis revealed an inverse correlation
between BCL6 and cyclin D2 expression in the group of HB-EGF-
positive human gastric cancers. Thus, we found that BCL6
expression correlated with the downregulation of cyclin D2
expression in human gastric cancer tissues that are HB-EGF
positive.
CD
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Cyclin D2
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Cyclin D2 Cyclin D2 Cyclin D2
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Figure 7 Immunohistochemistry of human gastric cancers. (A–H) Differentiated gastric cancer and (I–P) undifferentiated gastric cancer. (A and B) H&E
staining; (C and D) BCL6 detected in the nucleus and cytoplasm of cancer cells; (E and F) cyclin D2 was negative; (G and H) HB-EGF was detected in
the cytoplasm of cancer cells; (I and J) H&E staining; (K and L) BCL6 was negative; (M and N) cyclin D2 nuclear staining is observed in cancer cells; and
(O and P) HB-EGF was detected in the cytoplasm of cancer cells. (Original magnification: A, C, E, G, I, K, M, O  100; B, D, F, H, J, L, N, P  400).
Table 2 Relationship between BCL6 and cyclin D2
BCL6 (+) BCL6 ( ) Total P-value
(A) HB-EGF (+) group
Cyclin D2 (+) 2 18 20
Cyclin D2 ( ) 11 17 28 0.02
13 35 48
(B) HB-EGF ( ) group
Cyclin D2 (+) 2 14 16
Cyclin D2 ( ) 9 27 36 0.3
11 41 52
BCL6 function in gastric cancers
Y Hirata et al
1327
British Journal of Cancer (2009) 100(8), 1320–1329 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sWe also found that BCL6 expression was correlated with
histological types. BCL6 was highly expressed in differentiated
cancers and was remarkably reduced or absent in undifferentiated
cancers. Previous studies of gastric cancers have found that genes
such as BUB1, eRF3/GSPT1, and hCG-1 were correlated with
histological type (Grabsch et al, 2004; Malta-Vacas et al, 2005;
Liu et al, 2007). However, the precise mechanism of association
between the expression of these genes and the histology of gastric
cancer is not well understood. There have been no previous reports
of the relationship between BCL6 and gastric cancer histological
type. Nitti et al (2002) reported that low p27
kip1 protein expression,
which is involved in cell-cycle control and apoptosis, is associated
with poorly differentiated and advanced tumours. This data
indicate that cell-cycle acceleration is associated with advanced
undifferentiated cancers. Our present data reveal that BCL6
expression is reduced in undifferentiated gastric cancers. On the
basis of these results, we speculate that in undifferentiated gastric
cancers, the degradation of BCL6 induces cell-cycle accelera-
tion through cyclin D2 expression and that this cell-cycle
acceleration might be associated with undifferentiated gastric
cancers. BCL6 expression levels in differentiated and undiffer-
entiated gastric cancers may provide further evidence in gastric
cancer progression.
In conclusion, this is the first report to investigate the
transcriptional repressor BCL6 in gastric cancers. Our results
indicate that the nuclear export and the degradation of BCL6
caused by the interaction with HB-EGF-CTF are apparently linked
to cyclin D2 expression. These phenomena are shown in human
gastric cancer cases as well as in gastric cancer cell lines. BCL6
expression is also associated with differentiated gastric cancers.
Inhibition of HB-EGF-CTF nuclear translocation and maintenance
of BCL6 function are important factors in the regulation of gastric
cancer progression.
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